Magic mushroom compound tested for OCD in small trial

NCT ID NCT06992999

Not yet recruiting Symptom relief Sponsor: Francisco A Moreno Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test whether psilocybin, the active ingredient in magic mushrooms, can safely reduce symptoms of obsessive-compulsive disorder (OCD). Twenty adults with moderate-to-severe OCD who haven't responded to standard treatments will receive either a low (10mg) or high (30mg) dose in four supervised sessions over 12 weeks. Researchers will monitor safety, symptom changes, and brain activity using fMRI and EEG.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new treatment option for people with OCD who haven't improved with standard therapies.
What could go wrong: This is a very small, early-phase trial (Phase 1/2) with only 20 people. It primarily tests safety, not effectiveness. High doses may cause intense altered states, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder obsessive-compulsive personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSESSIVE-COMPULSIVE DISORDER

Contacts and locations

Locations

University of Arizona-Tucson

Tucson, Arizona, 85724, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.